Results of a study shared at the eight Vaccine & ISV Congress in Philadelphia on Sunday showed that pregnant women may benefit from the Novavax, Inc., respiratory syncytial virus (RSV) F-Protein Nanoparticle vaccine.
In clinical studies, 330 women of childbearing age were given either the vaccine for RSV or a placebo. While 20 percent of the placebo recipients showed signs of RSV, just 10 percent of the vaccine recipients showed signs of the infection. These findings demonstrate a 50 percent decrease in infection rates in the immunized participants.
Led by Dr. Gregory Glenn, Novavax researchers timed the vaccinations in such a way that participants passed through an estimation of the RSV season (December-March).
RSV causes infections of the lower respiratory tract and is particularly harmful to the young, elderly and those with compromised immune systems.Glenn plans on starting clinical trials on pregnant women, children and the elderly later this year.